Innovations Needed and Future Directions in Treatment of NSCLC
Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.
Source: ajmc.com
Egfr Mutation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Egfr Mutation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Egfr Mutation Today - Breaking & Trending Today
Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.
Source: onclive.com
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Source: onclive.com
Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer
Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.
Source: onclive.com
Adjuvant Osimertinib Provides OS Benefit in EGFR+ Stage IB-IIIA NSCLC
Treatment with adjuvant osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with resected, EGFR-mutated, stage IB to IIIA non–small cell lung cancer.
Source: onclive.com